drugset / Trial / NCT04634409
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Phase 2
Completed
1755 enrolled
Eli Lilly and Company
AbCellera Biologics Inc. · collabGlaxoSmithKline · collabShanghai Junshi Bioscience Co., Ltd. · collabVir Biotechnology, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the remainder of assessments performed in the home, local clinic, or by phone.
Timeline
- Start
- 2020-10-29
- Primary completion
- 2021-07-27
- Completion
- 2021-10-18
Publications
- Nichols RM, Macpherson L, Patel DR, Yeh WW, Peppercorn A. Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial. Infect Dis Ther. 2024 Feb;13(2):401-411. doi: 10.1007/s40121-024-00918-1. Epub 2024 Jan 30.
- Hirsch C, Park YS, Piechotta V, Chai KL, Estcourt LJ, Monsef I, Salomon S, Wood EM, So-Osman C, McQuilten Z, Spinner CD, Malin JJ, Stegemann M, Skoetz N, Kreuzberger N. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2.
- Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
- Nathan R, Shawa I, De La Torre I, Pustizzi JM, Haustrup N, Patel DR, Huhn G. A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2. Infect Dis Ther. 2021 Dec;10(4):1933-1947. doi: 10.1007/s40121-021-00515-6. Epub 2021 Aug 10.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bamlanivimab | Monoclonal antibody | 175 mg | Intravenous |
| Subject | Bamlanivimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Bamlanivimab | Monoclonal antibody | 700 mg | Intravenous |
| Subject | Bamlanivimab | Monoclonal antibody | 2800 mg | Intravenous |
| Subject | Bebtelovimab | Monoclonal antibody | 70 mg | Intravenous |
| Subject | Bebtelovimab | Monoclonal antibody | 175 mg | Intravenous |
| Subject | Bebtelovimab | Monoclonal antibody | 280 mg | Intravenous |
| Subject | Bebtelovimab | Monoclonal antibody | 560 mg | Intravenous |
| Subject | Bebtelovimab | Monoclonal antibody | 1400 mg | Intravenous |
| Subject | Bebtelovimab | Monoclonal antibody | 1750 mg | Intravenous |
| Subject | Etesevimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Etesevimab | Monoclonal antibody | 700 mg | Intravenous |
| Subject | Etesevimab | Monoclonal antibody | 1400 mg | Intravenous |
| Subject | Etesevimab | Monoclonal antibody | 2800 mg | Intravenous |
| Subject | Sotrovimab | Monoclonal antibody | 500 mg | Intravenous |